Glycotoxins in the diet promote diabetes and diabetic complications

Current Diabetes Reports

Volumn 7, Issue 3, 2007, Pages 235-241

  Vlassara, Helen ^a   Striker, Gary ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; CARBOHYDRATE; GLUCOSE; GLUTATHIONE; LIPID; METHYLGLYOXAL; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CONCENTRATION (PARAMETERS); COOKING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DIETARY INTAKE; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; FOOD COMPOSITION; GENE TARGETING; GLUCOSE BLOOD LEVEL; HIGH TEMPERATURE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; THERMAL EXPOSURE; UPREGULATION;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIET; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS;

EID: 34250726548     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0037-z     Document Type: Review

References (49)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977-986.
2. Monnier VM, Bautista O, Kenny D, et al.: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Diabetes 1999, 48:870-880.
3. Maillard LC: Action des acides amines sur les sucres: formation des malaniodines par voie methodique. C R Acad Sci 1912, 154:66-68.
4. Cai W, Gao QD, Zhu L, et al.: Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002, 8:337-346.
5. Goldberg T, Cai W, Peppa M, et al.: Advanced glycoxidation endproducts in commonly consumed foods. J Am Diet Assoc 2004, 104:1287-1291.
6. Vlassara H, Cai W, Crandall J, et al.: Inflammatory mediators are induced by dietary glycotoxins: a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002, 99:15596-15601.
7. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW: Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998, 273:18714-18719.
8. Miyata T, van Ypersele C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999, 55:389-399.
9. Bucala R, Makita Z, Koschinsky T, et al.: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993, 90:6434-6438.
10. Abordo EA, Minhas HS, Thornalley PJ: Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem Pharmacol 1999, 58:641-648.
11. Vander Jagt DL, Hunsaker LA: Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-1, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact 2003, 143-144; 341-351.
12. Anderson MM, Requena JR, Crowley JR, et al.: The myeloperoxidase system of human phagocytes generates N(epsilon)-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999, 104:103-113.
13. Dumitriu IE, Baruah P, Valentinis B, et al.: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005, 174:7506-7515.
14. Hori O, Brett J, Slattery T, et al.: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 1995, 270:25752-25761.
15. Kaneko M, Bucciarelli L, Hwang YC, et al.: Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci 2005, 1043:702-709.
16. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
17. Sandu O, Song K, Cai W, et al.: Insulin resistance and type 2 diabetes in high-fat fed mice is linked to high glycotoxin intake. Diabetes 2005, 54:2314-2319.
18. Lin RY, Choudhury RP, Cai W, et al.: Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003, 168:213-220.
19. Zheng F, He C, Cai W, et al.: Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002, 18:224-237.
20. Koschinsky T, He CJ, Mitsuhashi T, et al.: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997, 94:6474-6479.
21. Uribarri J, Peppa M, Cai W, et al.: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003, 14:728-731.
22. Uribarri J, Cai W, Peppa M, et al.: Circulating glycotoxins and dietary AGEs: two links to inflammatory response, oxidative stress and aging. J Gerontol 2007, In press.
23. Vlassara H: Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005, 1043:452-460.
24. Martindale JL, Holbrook NJ: Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002, 192:1-15.
25. Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Intern Med 2002, 251:87-101.
26. Lee CK, Klopp RG, Weindruch R, Prolla TA: Gene expression profile of aging and its retardation by caloric restriction. Science 1999, 285:1390-1393.
27. Harris TB, Ferrucci L, Tracy RP, et al.: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512.
28. Vlassara H, Brownlee M, Manogue K, et al.: Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 1988, 240:1546-1548.
29. Shangan N, Bruce WB, Poon R, O'Brien: Toxicity of glyoxals - role of oxidative stress, metabolic detoxification and thiamine deficiency. Biocbem Soc Trans 2003, 31:1390-1393.
30. Liu H, Zheng F, Cao Q, et al.: Amelioration of oxidant stress by the defensin lysozyme. Am J Physiol 2006, 290: E824-E832.
31. Lu C, He JC, Cai W, et al.: Advanced glycation end product (AGE) receptor 1 is a negative regulator of the inflammatory response to advanced glycation endproducts in mesangial cells. Proc Natl Acad Sci U S A 2004, 101:11767-11772.
32. Schmidt AM, Hori O, Brett J, et al.: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994, 14:1521-1528.
33. He C, Koschinsky T, Buenting C, Vlassara H: Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear AGE-receptor-1 and elevated serum AGE. Mol Med 2001, 7:159-168.
34. Wautier MP, Chappey O, Corda S, et al.: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280:E685-E694.
35. Huebschmann AG, Judith G, Regensteiner JG, et al.: Diabetes and advanced glycoxidation end products. Diabetes Care 2006, 29:1420-1432.
36. Foley RN, Murray AM, Li S, et al.: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
37. Murata T, Nagai R, Ishibashi T, et al.: The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997, 40:764-769.
38. McCance DR, Dyer DG, Dunn JA, et al.: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993, 91:2470-2478.
39. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002, 287:2570-2581.
40. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582-592.
41. Airaksinen KE, Salmela PI, Linnaluoto MK, et al.: Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 1993, 27:942-945.
42. Schram MT, Henry RM, van Dijk RA, et al.: Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 2004, 43:176-181.
43. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al.: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl A cad Sci U S A 1998, 95:4630-4634.
44. Soulis T, Cooper ME, Sastra S, et al.: Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997, 40:1141-1151.
45. Hammes HP, Strodter D, Weiss A, et al.: Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995, 38:656-660.
46. Brownlee M, Vlassara H, Kooney A, et al.: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
47. Degenhardt TP, Alderson NL, Arrington DD, et al.: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002, 61:939-950.
48. Hammes HP, Du X, Edelstein D, et al.: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294-299.
49. Cai W, He JC, Zhu L, et al.: Enhanced AGER1 expression, low oxidant stress and extended lifespan in mice exposed to a low glycoxidant diet. Am J Pathol 2007, In press.